RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
February 13, 2017 1:14 PM ESTMaxim Group lowered its price target on Teva Pharma (NYSE: TEVA) to $40.00 (from $41.00) while maintaining a Hold rating following results this morning.
Analyst Gabrielle Zhou commented, "This morning, Teva reported 4Q16 and full year results; total quarterly revenues were $6.5B, up 16.7% sequentially. Revenues... More
Teva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms
February 13, 2017 6:43 AM EST(Updated - February 13, 2017 6:44 AM EST)
Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.38, $0.02 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.26 billion.
Teva reaffirms its 2017 full year non-GAAP guidance; including revenues of $23.8 - 24.5 billion, and non-GAAP EPS of $4.90 - 5.30
"2016 was a transitional year for Teva - one that... More
